
# Q1, Q2, Q3 Data Dictionaries

## Q1 Data Dictionary

|          Variable name              | Definition of the variable                                                      | Settings and their definitions                                               |
|-------------------------------------|---------------------------------------------------------------------------------|------------------------------------------------------------------------------|
|setting	                          |Setting of data collection:	                                                    |1, Cruise ship <br /> 2, Hospital<br /> 3, Traveler/evacuee from an affected area<br /> 6, Contact tracing<br /> 7, Health care worker<br /> 9, Family cluster<br /> 88, Other|
|setting 2	                          |Setting 2 [used in Q1, Q2 analysis]                                              |1, 1. Contact investigation <br />2, 2. Contact investigation, aggregated <br /> 3, 3. Outbreak investigation <br /> 4, 4. Statistical model <br /> 5, 5. Screening <br /> 6, 6. Hospitalised adults <br /> 7, 7. Hospitalised children <br /> 8, 8. Hospitalised children and adults <br />9, 9. Screening: institutional setting <br />10, 10. Screening: community setting<br /> 11, 11. Screening: occupational|
|q1_nclus	                          |Number of clusters described:                                                    |1, One cluster <br /> 2, Two clusters|
|q1_c1_event	                      |Number of individuals that were asymptomatic throughout infection:               |	-                                         |	
|q1_c1_total                          |Total number of individuals (denominator):                                       |	-|
|q1_c2_event                          |Number of individuals that were asymptomatic throughout infection [cluster2]:    |	-|
|q1_c2_total                          |Total number of individuals (denominator) [cluster2]:                            |	-|
|q1_c3_event                          |Number of individuals that were asymptomatic throughout infection [cluster3]:    |	-|
|q1_c3_total                          |Total number of individuals (denominator) [cluster3]:                            |	-|
|comment_q1                           |Comments:                                                                        |	-|
|source	                              |Source:	                                                                        |1, MedRxiv <br /> 2, BioRxiv <br /> 3, EMBASE<br /> 4, PubMed <br /> 5, Other|
|Year                                 |Publication year:                                                                |	-	|
|country							  |Country:                                                                         |1, Afghanistan<br />2, Albania<br />3, Algeria<br />4, Andorra<br />5, Angola<br />6, Antigua and Barbuda<br />7, Argentina<br />8, Armenia<br />9, Aruba<br />10, Australia<br />11, Austria<br />12, Azawad<br />13, Azerbaijan<br />14, Bahamas<br />15, Bahrain<br />16, Bangladesh<br />17, Barbados<br />18, Belarus<br />19, Belgium<br />20, Belize<br />21, Benin<br />22, Bermuda<br />23, Bhutan<br />24, Bolivia<br />25, Bosnia and Herzegovina<br />26, Botswana<br />27, Brazil<br />28, Brunei<br />29, Bulgaria<br />30, Burkina Faso<br />31, Burundi<br />32, Cambodia<br />33, Cameroon<br />34, Canada<br />35, Cape Verde<br />36, Central African Republic<br />37, Chad<br />38, Chechnya<br />39, Chile<br />40, China<br />41, Colombia<br />42, Comoros<br />43, Congo<br />44, Costa Rica<br />45, Côte d'Ivoire<br />46, Croatia<br />47, Cuba<br />48, Curaçao<br />49, Cyprus<br />50, Czechoslovakia<br />51, Denmark<br />52, Dominican Republic<br />53, Ecuador<br />54, Egypt<br />55, El Salvador<br />56, Equatorial Guinea<br />57, Eritrea<br />58, Estonia<br />59, Ethiopia<br />60, Fiji<br />61, Finland<br />62, France<br />63, French Guyana<br />64, Gabon<br />65, Gambia<br />66, Georgia<br />67, Germany<br />68, Ghana<br />69, Greece<br />70, Greenland<br />71, Guatemala<br />72, Guinea<br />73, Guyana<br />74, Haiti<br />75, Honduras<br />76, Hong Kong<br />77, Hungary<br />78, Iceland<br />79, India<br />80, Indonesia<br />81, Iran<br />82, Iraq<br />83, Ireland<br />84, Israel<br />85, Italy<br />86, Jamaica<br />87, Japan<br />88, Jordan<br />89, Kazakhstan<br />90, Kenya<br />91, Kosovo<br />92, Kuwait<br />93, Kyrgyzstan<br />94, Laos<br />95, Latvia<br />96, Lebanon<br />97, Liberia<br />98, Libya<br />99, Liechtenstein<br />100, Lithuania<br />101, Luxembourg<br />102, Macedonia<br />103, Madagascar<br />104, Malawi<br />105, Malaysia<br />106, Maldives<br />107, Mali<br />108, Malta<br />109, Mauritius<br />110, Mexico<br />111, Moldova<br />112, Monaco<br />113, Mongolia<br />114, Montenegro<br />115, Morocco<br />116, Mozambique<br />117, Myanmar<br />118, Multiple<br />119, Namibia<br />120, Nepal<br />121, Netherlands<br />122, New Zealand<br />123, Nicaragua<br />124, Niger<br />125, Nigeria<br />126, North Korea<br />127, North Yemen<br />128, Norway<br />129, Oman<br />130, Pakistan<br />131, Palestine<br />132, Panama<br />133, Papua New Guinea<br />134, Paraguay<br />135, Peru<br />136, Philippines<br />137, Poland<br />138, Portugal<br />139, Puerto Rico<br />140, Qatar<br />141, Romania<br />142, Russia<br />143, Rwanda<br />144, Samoa<br />145, San Marino<br />146, Saudi Arabia<br />147, Senegal<br />148, Serbia<br />149, Seychelles<br />150, Sierra Leone<br />151, Singapore<br />152, Slovakia<br />153, Slovenia<br />154, Solomon Islands<br />155, Somalia<br />156, South Africa<br />157, South Korea<br />158, South Sudan<br />159, South Yemen<br />160, Spain<br />161, Sri Lanka<br />162, Sudan<br />163, Suriname<br />164, Swaziland<br />165, Sweden<br />166, Switzerland<br />167, Syria<br />168, Tajikistan<br />169, Tanzania<br />170, Thailand<br />171, Tibet<br />172, Togo<br />173, Tunisia<br />174, Turkey<br />175, Turkmenistan<br />176, Uganda<br />177, Ukraine<br />178, United Arab Emirates<br />179, United Arab Republic<br />180, United Kingdom<br />181, United States of America<br />182, Uruguay<br />183, Uzbekistan<br />184, Venezuela<br />185, Vietnam<br />186, Yemen<br />187, Yugoslavia<br />188, Zambia<br />189, Zanzibar<br />190, Zimbabwe<br />191, Sao Tome and Principe<br />200, More than one country<br />888, Other|
|region	                              |Region or comments from "country":                                               |	-	|
|q1_female                            |Number of females who remained asymptomatic throughout infection:                |	-|	
|q1_male                              |Number of males who remained asymptomatic throughout infection:                  |	-	|
|q1_age_median                        |Median age of all people who remained asymptomatic throughout infection:         |	-|	
|q1_age_iqr	                          |IQR for age of all people who remained asymptomatic throughout infection:|	-	|
|fup___1                              |Duration of follow-up time:                                                      |1, 14 days after the last possible exposure date|
|fup___2                              |Duration of follow-up time:                                                      |2, 7 days after diagnosis|
|fup___3                              |Duration of follow-up time:   													|3, Until negative PCR result|
|fup___4                              |Duration of follow-up time:														|4, >7 days after diagnosis|
|risk_of_bias_update_3_complete       |Complete?																		|0, Incomplete <br />1, Unverified <br />2, Complete|
|rob_1								  |(Consensus) Question 1- Was the sample invited to participate a close or true representation of the target population?|	1, High <br />2, Unclear <br />3, Low|
|rob_1_c2							  |(Consensus) Question 1- Was the sample invited in cluster 2 to participate a close or true representation of the target population?|	1, High<br />2, Unclear<br /> 3, Low|
|rob_2								  |(Consensus) Q2- The characteristics of non-respondents, if any, who were eligible are similar to those who participated in the study?|	1, High<br />2, Unclear <br /> 3, Low|
|rob_2_c2							  |(Consensus) Q2- The characteristics of non-respondents, if any, who were eligible are similar to those who participated in the study for cluster 2?|	1, High<br />2, Unclear <br />3, Low|
|rob_3								  |(Consensus) Q3- Was the assessment of symptoms status adequate?|	1, High<br />2, Unclear<br />3, Low|
|rob_3_c2							  |(Consensus) Q3- Was the assessment of symptoms status adequate for cluster 2?|	1, High<br />2, Unclear<br />3, Low|
|rob_4								  |(Consensus) Q4- Based on the method symptoms were collected, is there a risk of recall bias?|1, High<br />2, Unclear<br />3, Low|
|rob_4_c2							  |(Consensus) Q4- Based on the method symptoms were collected, is there a risk of recall bias for cluster 2?|	1, High<br />2, Unclear<br />3, Low|
|rob_5								  |(Consensus) Q5- Is there a risk that asymptomatic status was misclassified?|	1, High<br />2, Unclear<br />3, Low|
|rob_5_c2							  |(Consensus) Q5- Is there a risk that asymptomatic status was misclassified in cluster 2?|	1, High<br />2, Unclear<br />3, Low|
|rob_6								  |(Consensus) Q6- Is there a risk of incomplete or selective reporting of symptoms status?|	1, High<br />2, Unclear<br />3, Low|
|rob_6_c2							  |(Consensus) Q6- Is there a risk of incomplete or selective reporting of symptoms status in cluster 2?|	1, High<br />2, Unclear<br />3, Low|
|agerange___1						  |Age range of asymptomatic |1, Children (< 18 years)|
|agerange___2						  |Age range of asymptomatic |2, Adults (18 - 65 years)|
|agerange___3						  |Age range of asymptomatic |3, Older adults (>65 years)|
|agerange___4						  |Age range of asymptomatic |4, All ages|
|agerange___5						  |Age range of asymptomatic |5, Not Reported|

